292636-09-0

Basic information

• Product Name: 7-BROMO-4-FLUOROINDOLE
• Synonyms: 7-BROMO-4-FLUOROINDOLE;4-fluoro-7-Bromoindole;1H-Indole, 7-broMo-4-fluoro-
• CAS NO: 292636-09-0
• Molecular Formula: C₈H₅BrFN
• Molecular Weight: 214.03
• Mol File: 292636-09-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 314.2 °C at 760 mmHg
• Flash Point: 143.8 °C
• Appearance: /
• Density: 1.75 g/cm³
• Vapor Pressure: 0.000874mmHg at 25°C
• Refractive Index: 1.68
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 14.73±0.30(Predicted)
• Sensitive: Light Sensitive
• CAS DataBase Reference: 7-BROMO-4-FLUOROINDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BROMO-4-FLUOROINDOLE(292636-09-0)
• EPA Substance Registry System: 7-BROMO-4-FLUOROINDOLE(292636-09-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 292636-09-0(Hazardous Substances Data)

Usage

General Description

7-Bromo-4-fluoroindole is a chemical compound with the molecular formula C8H5BrFN and a molecular weight of 204.03 g/mol. It is a brominated and fluorinated derivative of indole, a heterocyclic aromatic compound commonly found in various natural products and pharmaceuticals. 7-Bromo-4-fluoroindole is used as a building block in the synthesis of pharmaceuticals and agrochemicals. Its unique structure and properties make it a valuable intermediate in the production of various compounds with potential therapeutic applications. It is important to handle this chemical with care and follow proper safety protocols due to its potential hazards. 7-BROMO-4-FLUOROINDOLE is not naturally occurring and is typically produced through synthetic chemical processes.

InChI:InChI=1/C8H5BrFN/c9-6-1-2-7(10)5-3-4-11-8(5)6/h1-4,11H

Upstream product

• 446-09-3 2-bromo-5-fluoronitrobenzene 
• 1826-67-1 vinyl magnesium bromide 
• 460-00-4 1-Bromo-4-fluorobenzene 

Downstream Products

• 313337-34-7 4-fluoroindole-7-carboxylic acid 
• 387-43-9 4-fluoroindole 
• 908600-72-6 4-fluoroindole-5-carboxylic acid 
• 344790-96-1 5-bromo-4-fluoro-1H-indole 
• 292636-13-6 4-fluoro-1H-indol-7-ylamine 
• 292636-23-8 N-(4-fluoro-1H-indol-7-yl)-4-nitro-benzenesulfonamide 
• 292636-22-7 N-(3-chloro-4-fluoro-1H-indol-7-yl)-4-nitro-benzenesulfonamide 
• 313337-33-6 4-fluoro-1H-indole-7-carbonitrile 
• 389628-19-7 4-fluoro-1H-indole-7-carbaldehyde 
• 389629-41-8 1-(4-Benzoyl-piperazin-1-yl)-2-(4-fluoro-7-[1,2,4]oxadiazol-3-yl-1H-indol-3-yl)-ethane-1,2-dione 
• 389628-78-8 1-(4-Benzoyl-piperazin-1-yl)-2-[4-fluoro-7-(2H-tetrazol-5-yl)-1H-indol-3-yl]-ethane-1,2-dione 
• 389628-23-3 C₂₂H₁₇FN₄O₃ 
• 389628-85-7 C₂₂H₂₀FN₅O₄ 
• 389629-09-8 3-[2-(4-benzoyl-piperazin-1-yl)-2-oxo-acetyl]-4-fluoro-1H-indole-7-carboxylic acid methylamide 

Relevant articles and documents

Field-based affinity optimization of a novel azabicyclohexane scaffold HIV-1 entry inhibitor

Small-molecule HIV-1 entry inhibitors are an extremely attractive therapeutic modality. We have previously demonstrated that the entry inhibitor class can be optimized by using computational means to identify and extend the chemotypes available. Here we demonstrate unique and differential effects of previously published antiviral compounds on the gross structure of the HIV-1 Env complex, with an azabicyclohexane scaffolded inhibitor having a positive effect on glycoprotein thermostability. We demonstrate that modification of the methyltriazole-azaindole headgroup of these entry inhibitors directly effects the potency of the compounds, and substitution of the methyltriazole with an amine-oxadiazole increases the affinity of the compound 1000-fold over parental by improving the on-rate kinetic parameter. These findings support the continuing exploration of compounds that shift the conformational equilibrium of HIV-1 Env as a novel strategy to improve future inhibitor and vaccine design efforts.

COMPOUNDS

The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

INDOLE CARBOXAMIDES AS IKK2 INHIBITORS

The invention is directed to novel indole carboxamide compounds. Specifically, the invention is directed to compounds according to formula (I): wherein R1, R2, R3, R4, and m are as defined herein. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.